1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 40 pages

Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2015’, provides an overview of the Celator Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celator Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Celator Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Celator Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Celator Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Celator Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Celator Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Celator Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Celator Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celator Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Celator Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Celator Pharmaceuticals, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Celator Pharmaceuticals, Inc. Snapshot 5
Celator Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Celator Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Celator Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Celator Pharmaceuticals, Inc. - Pipeline Products Glance 11
Celator Pharmaceuticals, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Celator Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Celator Pharmaceuticals, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Celator Pharmaceuticals, Inc. - Drug Profiles 16
(cytarabine hydrochloride + daunorubicin hydrochloride) 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
(irinotecan hydrochloride + floxuridine) 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
(irinotecan hydrochloride + cisplatin) 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
CPX-8 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Small Molecule 1 for oncology 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Small Molecules to Inhibit HDAC and DNA Methyltransferase for Oncology 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Small Molecules to Inhibit Tubulin for Oncology 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Celator Pharmaceuticals, Inc. - Pipeline Analysis 26
Celator Pharmaceuticals, Inc. - Pipeline Products by Target 26
Celator Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 27
Celator Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 28
Celator Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 29
Celator Pharmaceuticals, Inc. - Recent Pipeline Updates 30
Celator Pharmaceuticals, Inc. - Dormant Projects 37
Celator Pharmaceuticals, Inc. - Locations And Subsidiaries 38
Head Office 38
Other Locations and Subsidiaries 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

List of Tables
Celator Pharmaceuticals, Inc., Key Information 5
Celator Pharmaceuticals, Inc., Key Facts 5
Celator Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7
Celator Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
Celator Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
Celator Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015 10
Celator Pharmaceuticals, Inc. - Phase III, 2015 11
Celator Pharmaceuticals, Inc. - Phase II, 2015 12
Celator Pharmaceuticals, Inc. - Phase I, 2015 13
Celator Pharmaceuticals, Inc. - Preclinical, 2015 14
Celator Pharmaceuticals, Inc. - Discovery, 2015 15
Celator Pharmaceuticals, Inc. - Pipeline by Target, 2015 26
Celator Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 27
Celator Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 28
Celator Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 29
Celator Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 30
Celator Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 37
Celator Pharmaceuticals, Inc., Subsidiaries 38

List of Figures
Celator Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015 7
Celator Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
Celator Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
Celator Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015 10
Celator Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015 26
Celator Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015 27
Celator Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015 28
Celator Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.